The initial success of Viagra undeniably transformed the drug landscape, but placing funds in companies strongly reliant on generic versions presents a uncertain picture. While early returns were significant, the expiration of patents and the emergence of cheaper alternatives have weakened market share. Consequently, a thorough assessment of presen